This study evaluated the cost-utility of PCSK9 inhibitors (evolocumab, alirocumab, tafolecimab, and inclisiran) as adjuncts to statin therapy in Chinese patients with hypercholesterolemia or at high cardiovascular risk, using a Markov cohort multistate-transition model informed by LDL-C reductions from a network meta-analysis. Here, PCSK9 is linked to Hypercholesterolemia.